376 related articles for article (PubMed ID: 29791065)
1. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Zhu X; Li X; Zhang T; Zhao L
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
[TBL] [Abstract][Full Text] [Related]
2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
3. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
[TBL] [Abstract][Full Text] [Related]
4. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
6. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
[TBL] [Abstract][Full Text] [Related]
7. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
9. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
[TBL] [Abstract][Full Text] [Related]
10. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
[TBL] [Abstract][Full Text] [Related]
12. CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
Chen L; Tian Q; Zhang M; Chen D; Gao X; Yang H; Li H; Li C; Wen J; Li Y; Tian X; Chen P
Epilepsy Res; 2019 Aug; 154():139-143. PubMed ID: 31151073
[TBL] [Abstract][Full Text] [Related]
13. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
14. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
Böhles H; Sewell AC; Wenzel D
Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
[TBL] [Abstract][Full Text] [Related]
15. Association of valproic acid and 2-propyl-4-pentenoic acid concentrations with adverse reaction in 254 Chinese patients with epilepsy.
Ma H; Zhu W; Wang C; Pan J; Yang X; Luo J; Wang P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Jul; 44(7):775-783. PubMed ID: 31413215
[TBL] [Abstract][Full Text] [Related]
16. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
[TBL] [Abstract][Full Text] [Related]
18. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
[TBL] [Abstract][Full Text] [Related]
19. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
